<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">        <PMID Version="1">30233821</PMID>        <DateRevised>            <Year>2018</Year>            <Month>11</Month>            <Day>14</Day>        </DateRevised>        <Article PubModel="Electronic-eCollection">            <Journal>                <ISSN IssnType="Print">2059-7029</ISSN>                <JournalIssue CitedMedium="Print">                    <Volume>3</Volume>                    <Issue>6</Issue>                    <PubDate>                        <Year>2018</Year>                    </PubDate>                </JournalIssue>                <Title>ESMO open</Title>                <ISOAbbreviation>ESMO Open</ISOAbbreviation>            </Journal>            <ArticleTitle>Somatic cancer genetics in the UK: real-world data from phase I of the Cancer Research UK Stratified Medicine Programme.</ArticleTitle>            <Pagination>                <MedlinePgn>e000408</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.1136/esmoopen-2018-000408</ELocationID>            <Abstract>                <AbstractText Label="Introduction" NlmCategory="UNASSIGNED">Phase I of the Cancer Research UK Stratified Medicine Programme (SMP1) was designed to roll out molecular pathology testing nationwide at the point of cancer diagnosis, as well as facilitate an infrastructure where surplus cancer tissue could be used for research. It offered a non-trial setting to examine common UK cancer genetics in a real-world context.</AbstractText>                <AbstractText Label="Methods" NlmCategory="UNASSIGNED">A total of 26 sites in England, Wales and Scotland, recruited samples from 7814 patients for genetic examination between 2011 and 2013. Tumour types involved were breast, colorectal, lung, prostate, ovarian cancer and malignant melanoma. Centralised molecular testing of surplus material from resections or biopsies of primary/metastatic tissue was performed, with samples examined for 3-5 genetic alterations deemed to be of key interest in site-specific cancers by the National Cancer Research Institute Clinical Study groups.</AbstractText>                <AbstractText Label="Results" NlmCategory="UNASSIGNED">10â€‰754 patients (98% of those approached) consented to participate, from which 7814 tumour samples were genetically analysed. In total, 53% had at least one genetic aberration detected. From 1885 patients with lung cancer, <i>KRAS</i> mutation was noted to be highly prevalent in adenocarcinoma (37%). In breast cancer (1873 patients), there was a striking contrast in <i>TP53</i> mutation incidence between patients with ductal cancer (27.3%) and lobular cancer (3.4%). Vast inter-tumour heterogeneity of colorectal cancer (1550 patients) was observed, including myriad double and triple combinations of genetic aberrations. Significant losses of important clinical information included smoking status in lung cancer and loss of distinction between low-grade and high-grade serous ovarian cancers.</AbstractText>                <AbstractText Label="Conclusion" NlmCategory="UNASSIGNED">Nationwide molecular pathology testing in a non-trial setting is feasible. The experience with SMP1 has been used to inform ongoing CRUK flagship programmes such as the CRUK National Lung MATRIX trial and TRACERx.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Lindsay</LastName>                    <ForeName>Colin R</ForeName>                    <Initials>CR</Initials>                    <Identifier Source="ORCID">0000-0001-8167-5461</Identifier>                    <AffiliationInfo>                        <Affiliation>Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Manchester Experimental Cancer Medicine Centre, Manchester, UK.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Division of Molecular and Clinical Cancer Sciences, University of Manchester, Manchester, UK.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Shaw</LastName>                    <ForeName>Emily C</ForeName>                    <Initials>EC</Initials>                    <AffiliationInfo>                        <Affiliation>Cancer Research UK, London, UK.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Southampton Experimental Cancer Medicine Centre, Southampton, UK.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Blackhall</LastName>                    <ForeName>Fiona</ForeName>                    <Initials>F</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Manchester Experimental Cancer Medicine Centre, Manchester, UK.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Division of Molecular and Clinical Cancer Sciences, University of Manchester, Manchester, UK.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Blyth</LastName>                    <ForeName>Kevin G</ForeName>                    <Initials>KG</Initials>                    <AffiliationInfo>                        <Affiliation>Glasgow Experimental Cancer Medicine Centre, Glasgow, UK.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Respiratory Medicine, Queen Elizabeth University Hospital, Glasgow, UK.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Institute ofInfection, Immunity and Inflammation, University of Glasgow, Glasgow, UK.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Brenton</LastName>                    <ForeName>James D</ForeName>                    <Initials>JD</Initials>                    <AffiliationInfo>                        <Affiliation>Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Cancer Research UK Cambridge Centre and Cambridge Experimental Cancer Medicine Centre, Cambridge, UK.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Addenbrooke'sHospital, Cambridge University Hospital NHS Foundation Trust, Cambridge, UK.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Chaturvedi</LastName>                    <ForeName>Anshuman</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Histopathology, University Hospital of South Manchester NHS Foundation Trust, Manchester, UK.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Christie and Salford Royal NHS Foundation Trusts, Manchester, UK.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Clarke</LastName>                    <ForeName>Noel</ForeName>                    <Initials>N</Initials>                    <AffiliationInfo>                        <Affiliation>Christie and Salford Royal NHS Foundation Trusts, Manchester, UK.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Dick</LastName>                    <ForeName>Craig</ForeName>                    <Initials>C</Initials>                    <AffiliationInfo>                        <Affiliation>Glasgow Experimental Cancer Medicine Centre, Glasgow, UK.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Pathology, Queen Elizabeth University Hospital, Glasgow, UK.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Evans</LastName>                    <ForeName>Thomas R J</ForeName>                    <Initials>TRJ</Initials>                    <AffiliationInfo>                        <Affiliation>Glasgow Experimental Cancer Medicine Centre, Glasgow, UK.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Cancer Research UK Beatson Institute, Glasgow, UK.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Institute of Cancer Sciences, University of Glasgow, Glasgow, UK.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Hall</LastName>                    <ForeName>Geoff</ForeName>                    <Initials>G</Initials>                    <AffiliationInfo>                        <Affiliation>Leeds Experimental Cancer Medicine Centre, Leeds, UK.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>St James's University Hospital, Cancer Research UK Clinical Cancer Centre, Leeds, UK.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Hanby</LastName>                    <ForeName>Andrew M</ForeName>                    <Initials>AM</Initials>                    <AffiliationInfo>                        <Affiliation>Leeds Experimental Cancer Medicine Centre, Leeds, UK.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Cellular Pathology, Leeds Teaching Hospitals NHS Trust, Leeds, UK.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>School of Medicine, University of Leeds, Leeds, UK.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Pathology and Tumour Biology, Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, UK.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Harrison</LastName>                    <ForeName>David J</ForeName>                    <Initials>DJ</Initials>                    <AffiliationInfo>                        <Affiliation>School of Medicine, University of St Andrews, St Andrews, UK.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Edinburgh Experimental Cancer Medicine Centre, Edinburgh, UK.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Johnston</LastName>                    <ForeName>Stephen R D</ForeName>                    <Initials>SRD</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Medical Oncology, Royal Marsden Hospital, London, UK.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Institute of Cancer Research Experimental Cancer Medicine Centre, London, UK.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Mason</LastName>                    <ForeName>Malcolm D</ForeName>                    <Initials>MD</Initials>                    <AffiliationInfo>                        <Affiliation>Velindre Hospital, Cardiff University, Cardiff, UK.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>School of Medicine, Cardiff University, Cardiff, UK.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Cardiff Experimental Cancer Medicine Centre, Cardiff, UK.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Morton</LastName>                    <ForeName>Dion</ForeName>                    <Initials>D</Initials>                    <AffiliationInfo>                        <Affiliation>Academic Department of Surgery, University of Birmingham, Birmingham, UK.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Birmingham Experimental Cancer Medicine Centre, Birmingham, UK.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Newton-Bishop</LastName>                    <ForeName>Julia</ForeName>                    <Initials>J</Initials>                    <AffiliationInfo>                        <Affiliation>Leeds Experimental Cancer Medicine Centre, Leeds, UK.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Section of Biostatistics and Epidemiology, Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, UK.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Nicholson</LastName>                    <ForeName>Andrew G</ForeName>                    <Initials>AG</Initials>                    <AffiliationInfo>                        <Affiliation>Royal Brompton and Harefield NHS Foundation Trust, London, UK.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>National Heart and Lung Institute, Imperial College, London, UK.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Oien</LastName>                    <ForeName>Karin A</ForeName>                    <Initials>KA</Initials>                    <AffiliationInfo>                        <Affiliation>Glasgow Experimental Cancer Medicine Centre, Glasgow, UK.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Institute of Cancer Sciences, University of Glasgow, Glasgow, UK.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Popat</LastName>                    <ForeName>Sanjay</ForeName>                    <Initials>S</Initials>                    <AffiliationInfo>                        <Affiliation>Institute of Cancer Research Experimental Cancer Medicine Centre, London, UK.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>National Heart and Lung Institute, Imperial College, London, UK.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Lung Unit, Royal Marsden Hospital, London, UK.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Rassl</LastName>                    <ForeName>Doris</ForeName>                    <Initials>D</Initials>                    <AffiliationInfo>                        <Affiliation>Cancer Research UK Cambridge Centre and Cambridge Experimental Cancer Medicine Centre, Cambridge, UK.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Histopathology, Papworth Hospital, Cambridge, UK.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Sharpe</LastName>                    <ForeName>Rowena</ForeName>                    <Initials>R</Initials>                    <AffiliationInfo>                        <Affiliation>Cancer Research UK, London, UK.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Taniere</LastName>                    <ForeName>Phillipe</ForeName>                    <Initials>P</Initials>                    <AffiliationInfo>                        <Affiliation>Birmingham Experimental Cancer Medicine Centre, Birmingham, UK.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Histopathology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Walker</LastName>                    <ForeName>Ian</ForeName>                    <Initials>I</Initials>                    <AffiliationInfo>                        <Affiliation>Cancer Research UK, London, UK.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Wallace</LastName>                    <ForeName>William A</ForeName>                    <Initials>WA</Initials>                    <AffiliationInfo>                        <Affiliation>Edinburgh Experimental Cancer Medicine Centre, Edinburgh, UK.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Pathology, Laboratory Medicine, Royal Infirmary of Edinburgh, Edinburgh, UK.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>West</LastName>                    <ForeName>Nicholas P</ForeName>                    <Initials>NP</Initials>                    <AffiliationInfo>                        <Affiliation>Leeds Experimental Cancer Medicine Centre, Leeds, UK.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Pathology and Tumour Biology, Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, UK.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Butler</LastName>                    <ForeName>Rachel</ForeName>                    <Initials>R</Initials>                    <AffiliationInfo>                        <Affiliation>All Wales Genetics Laboratory, Cardiff, UK.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Gonzalez de Castro</LastName>                    <ForeName>David</ForeName>                    <Initials>D</Initials>                    <AffiliationInfo>                        <Affiliation>Genomic Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queen's University, Belfast, UK.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Griffiths</LastName>                    <ForeName>Mike</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>West Midlands Regional Genetics Laboratory, Birmingham Women's NHS Foundation Trust, Birmingham, UK.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Johnson</LastName>                    <ForeName>Peter W M</ForeName>                    <Initials>PWM</Initials>                    <AffiliationInfo>                        <Affiliation>Cancer Research UK, London, UK.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Southampton Experimental Cancer Medicine Centre, Southampton, UK.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>09</Month>                <Day>05</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>England</Country>            <MedlineTA>ESMO Open</MedlineTA>            <NlmUniqueID>101690685</NlmUniqueID>            <ISSNLinking>2059-7029</ISSNLinking>        </MedlineJournalInfo>        <CommentsCorrectionsList>            <CommentsCorrections RefType="Cites">                <RefSource>N Engl J Med. 2015 Apr 30;372(18):1700-9</RefSource>                <PMID Version="1">25923550</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>N Engl J Med. 2015 Jan 1;372(1):30-9</RefSource>                <PMID Version="1">25399551</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Eur J Hum Genet. 2016 Jul;24(7):1096</RefSource>                <PMID Version="1">27307115</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Nature. 2017 Apr 26;545(7655):446-451</RefSource>                <PMID Version="1">28445469</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Ann Oncol. 2015 Dec;26(12):2464-9</RefSource>                <PMID Version="1">26410619</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 2016 Mar 10;34(8):884-6</RefSource>                <PMID Version="1">26755521</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>N Engl J Med. 2017 Jun 1;376(22):2109-2121</RefSource>                <PMID Version="1">28445112</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Drug Discov Today. 2015 Dec;20(12):1414-8</RefSource>                <PMID Version="1">26232318</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>N Engl J Med. 2015 Apr 30;372(18):1689-99</RefSource>                <PMID Version="1">25923549</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Nat Rev Clin Oncol. 2012 Jul 10;9(8):479-86</RefSource>                <PMID Version="1">22777058</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Nature. 2008 Oct 23;455(7216):1069-75</RefSource>                <PMID Version="1">18948947</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Ann Oncol. 2011 Nov;22 Suppl 7:vii29-vii35</RefSource>                <PMID Version="1">22039142</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Lancet. 2016 Sep 3;388(10048):1002-11</RefSource>                <PMID Version="1">27598680</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Thorac Oncol. 2016 Jan;11(1):79-84</RefSource>                <PMID Version="1">26762742</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Expert Rev Mol Diagn. 2015 Mar;15(3):287-9</RefSource>                <PMID Version="1">25547183</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Nat Rev Cancer. 2014 May;14(5):291-2</RefSource>                <PMID Version="1">25688402</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Nat Med. 2015 Jun;21(6):560-2</RefSource>                <PMID Version="1">25939061</PMID>            </CommentsCorrections>        </CommentsCorrectionsList>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">cancer</Keyword>            <Keyword MajorTopicYN="N">cruk</Keyword>            <Keyword MajorTopicYN="N">genetic</Keyword>            <Keyword MajorTopicYN="N">lung</Keyword>            <Keyword MajorTopicYN="N">stratified medicine</Keyword>        </KeywordList>        <CoiStatement>Competing interests: Funding for the Stratified Medicine Programme is acknowledged from Cancer Research UK and programme founding partners AstraZeneca and Pfizer. For hosting the Stratified Medicine Programme data, thanks to the National Cancer Registration Service Eastern Office, Jim Davies and Steve Harris at the University of Oxford Department of Computer Science. AGN was supported by the National Institute of Health Research Respiratory Disease Biomedical Research Unit at the Royal Brompton and Harefield NHS Foundation Trust and Imperial College London. PJ, ES and CL have all been employed by Cancer Research UK in the past. FB was supported by Cancer Research UK Lung Cancer Centre of Excellence Funding. WAW was supported by Lothian NRS BioResource. SP acknowledges NHS funding to the NIHR Biomedical Research Centre at The Royal Marsden and the ICR. NPW was supported by Yorkshire Cancer Research. KGB was supported by a NHS Research Scotland Senior Fellowship.</CoiStatement>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>05</Month>                <Day>23</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="revised">                <Year>2018</Year>                <Month>05</Month>                <Day>30</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>05</Month>                <Day>31</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>9</Month>                <Day>21</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>9</Month>                <Day>21</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>9</Month>                <Day>21</Day>                <Hour>6</Hour>                <Minute>1</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>epublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30233821</ArticleId>            <ArticleId IdType="doi">10.1136/esmoopen-2018-000408</ArticleId>            <ArticleId IdType="pii">esmoopen-2018-000408</ArticleId>            <ArticleId IdType="pmc">PMC6135448</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>